B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $118 to $140.
May 25, 2023 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst maintains Buy rating on Krystal Biotech and raises price target from $118 to $140.
The raised price target by B of A Securities analyst Alec Stranahan indicates a positive outlook for Krystal Biotech's stock. This news is likely to have a positive impact on the stock price in the short term as it reflects increased confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100